Skip to main content
. Author manuscript; available in PMC: 2010 May 5.
Published in final edited form as: J Control Release. 2009 Feb 5;135(3):250–258. doi: 10.1016/j.jconrel.2009.01.020

Figure 1.

Figure 1

Adenovirus modified by DIG-NHS maintains its infectivity. (a) DIG-NHS treated AdLacZ was captured on ELISA plates to detect and quantify DIG molecules on viral surfaces with anti-DIG Ab-AP. The data suggest that the DIG modification was dose dependent and saturated when there were more than 0.075 nmole DIG-NHS per 109 viral particles. (b) The β-galactosidase expression from cells infected with AdLacZ with (solid line) and without (dashed line) DIG modification were compared by sandwich ELISA. The results demonstrate that there were no significant differences between these two groups with different virus concentrations, suggesting that this modification was mild, and that viral infectivity could be maintained.